Recensa Therapeutics
Recensa Therapeutics, Inc. has a new approach to treating psoriasis: topical therapies that reduce oxidative stress. Instead of modulating the immune system, Recensa’s Nrf2 Activators will leverage the body’s own antioxidants to stop the inflammatory cycle. Supported by the University City Science Center and using novel technology from Temple University, Recensa plans to be first-to-market with this new mechanism of action for the six million U.S. patients with mild-to-moderate psoriasis.
